2010
ABO Blood Group, Helicobacter pylori Seropositivity, and Risk of Pancreatic Cancer: A Case–Control Study
Risch HA, Yu H, Lu L, Kidd MS. ABO Blood Group, Helicobacter pylori Seropositivity, and Risk of Pancreatic Cancer: A Case–Control Study. Journal Of The National Cancer Institute 2010, 102: 502-505. PMID: 20181960, PMCID: PMC2902822, DOI: 10.1093/jnci/djq007.Peer-Reviewed Original ResearchMeSH KeywordsABO Blood-Group SystemAdultAgedAged, 80 and overAntibodies, BacterialAntigens, BacterialBacterial ProteinsCase-Control StudiesConfounding Factors, EpidemiologicConnecticutEnzyme-Linked Immunosorbent AssayFemaleHelicobacter InfectionsHelicobacter pyloriHumansIncidenceMaleMiddle AgedOdds RatioPancreatic NeoplasmsConceptsNon-O blood typeH pylori seropositivityCase-control studyPancreatic cancerPylori seropositivityABO blood groupEnzyme-linked immunosorbent assayBlood typeBlood groupPopulation-based case-control studyNon-O blood groupControl subjects frequencyH pylori colonizationVirulence protein CagAHelicobacter pylori seropositivityPancreatic cancer riskO blood typeRandom digit dialingCagA seropositivityCase patientsH pyloriControl subjectsRisk factorsPylori colonizationCancer risk
2009
Randomized Controlled Trial of Aerobic Exercise on Insulin and Insulin-like Growth Factors in Breast Cancer Survivors: The Yale Exercise and Survivorship Study
Irwin ML, Varma K, Alvarez-Reeves M, Cadmus L, Wiley A, Chung GG, DiPietro L, Mayne ST, Yu H. Randomized Controlled Trial of Aerobic Exercise on Insulin and Insulin-like Growth Factors in Breast Cancer Survivors: The Yale Exercise and Survivorship Study. Cancer Epidemiology Biomarkers & Prevention 2009, 18: 306-313. PMID: 19124513, PMCID: PMC2841479, DOI: 10.1158/1055-9965.epi-08-0531.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsPostmenopausal breast cancer survivorsModerate-intensity aerobic exerciseUsual care groupBreast cancer riskAerobic exerciseIGFBP-3Cancer survivorsUsual careCare groupCancer riskYale-New Haven Hospital Tumor RegistryCurrent physical activity levelsInsulin-like growth factorHospital tumor registryUsual care participantsAerobic exercise interventionExercise-induced decreasePhysical activity levelsInsulin-like growthExercise groupExercise interventionControlled TrialsTumor RegistryBrisk walking
2008
TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival
Mu L, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Yu H. TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival. British Journal Of Cancer 2008, 99: 1357-1363. PMID: 18827819, PMCID: PMC2570529, DOI: 10.1038/sj.bjc.6604689.Peer-Reviewed Original ResearchConceptsHigher TGF-β1TGF-β1 genotypesTGF-β1T genotypeHazard ratioBreast cancerBreast tumorsProportional hazards regression analysisLower TGF-β1Early-stage diseaseHazards regression analysisBreast cancer patientsLate-stage diseaseShorter overall survivalFresh tumor samplesTGF-β1 concentrationsBreast cancer progressionClinical characteristicsIGFBP-3Overall survivalDisease recurrenceReceptor statusPatient survivalSurvival outcomesDisease stage
2006
Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3)
Harris T, Strickler H, Yu H, Pollak M, Monrad E, Travin M, Xue X, Rohan T, Kaplan R. Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3). Growth Hormone & IGF Research 2006, 16: 86-92. PMID: 16530441, DOI: 10.1016/j.ghir.2006.01.002.Peer-Reviewed Original ResearchConceptsFree IGF-I levelsIGF-I levelsInsulin-like growth factorTotal IGFIGFBP-3 levelsFree IGFIGFBP-3Blood specimensBlood collectionEpidemiologic studiesTotal insulin-like growth factorSerum separation tubesGrowth factorRisk of cancerEquation linear regression modelsSerum levelsCardiovascular diseaseMajor binding proteinSerum valuesIGFCommercial assaysIGFBPSpecimen processing timeProtein 3Immunosorbent assay
2003
Assessment of Insulin-Like Growth Factors and Mutagen Sensitivity as Predictors of Lung Cancer Risk
Wu X, Yu H, Makan N, Spitz M. Assessment of Insulin-Like Growth Factors and Mutagen Sensitivity as Predictors of Lung Cancer Risk. Methods In Molecular Medicine 2003, 75: 279-287. PMID: 12407747, DOI: 10.1385/1-59259-324-0:279.Peer-Reviewed Original ResearchMeSH Keywords7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxideBleomycinChromatidsChromosome AberrationsEnzyme-Linked Immunosorbent AssayHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IInsulin-Like Growth Factor IILung NeoplasmsLymphocytesMutagenicity TestsMutagensPredictive Value of TestsRisk FactorsConceptsInsulin-like growth factorSignal transduction pathwaysGrowth factorCell cycle progressionCell membrane receptorsTransduction pathwaysBcl proteinsMAP kinaseLung cancer cellsIGF-1 receptorCell deathMembrane receptorsS phaseAntiproliferative moleculesBinding of IGFBax proteinCell proliferationLung cancer riskImportant functionsProteinCancer cellsCyclin D1Retinoic acidTypes of peptidesMitogenic action
2002
Plasma concentrations of insulin-like growth factors among healthy adult men and postmenopausal women: associations with body composition, lifestyle, and reproductive factors.
Chang S, Wu X, Yu H, Spitz M. Plasma concentrations of insulin-like growth factors among healthy adult men and postmenopausal women: associations with body composition, lifestyle, and reproductive factors. Cancer Epidemiology Biomarkers & Prevention 2002, 11: 758-66. PMID: 12163330.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBody CompositionCross-Sectional StudiesDietEnzyme-Linked Immunosorbent AssayFemaleHumansLife StyleMaleMiddle AgedPremenopauseRegression AnalysisSex FactorsSmokingSomatomedinsConceptsInsulin-like growth factorIGF BP-3 levelsBody mass indexBP-3 levelsIGF BP-3IGF-II levelsHormone replacement therapyIGF-I levelsLow physical activityIGF levelsIGF-IIPhysical activityPostmenopausal womenHRT useCaloric intakeReproductive factorsLower IGF-II levelsTraditional cancer risk factorsLow IGF-I levelsPlasma insulin-like growth factorHigher body mass indexGrowth factorIGF-BP levelsPlasma IGF-IIRecent HRT use
2001
IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival
Katsaros D, Yu H, Levesque M, Danese S, Genta F, Richiardi G, Fracchioli S, Khosravi M, Diamandi A, Gordini G, Diamandis E, Massobrio M. IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. European Journal Of Cancer 2001, 37: 478-485. PMID: 11267857, DOI: 10.1016/s0959-8049(00)00423-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorDisease-Free SurvivalEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesHumansInsulin-Like Growth Factor Binding Protein 3Middle AgedNeoplasm ProteinsNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPrognosisRisk FactorsConceptsIGFBP-3 levelsInsulin-like growth factorLower IGFBP-3 levelsEpithelial ovarian carcinomaIGFBP-3Overall survivalPatient survivalOvarian carcinomaGrowth factorUnfavourable prognostic featuresIGFBP-3 concentrationsClinico-pathological featuresEpithelial ovarian cancerPatients' overall survivalResponse of patientsOvarian cancer progressionAnti-apoptotic actionClinicopathological featuresPathological variablesPrognostic featuresResidual tumorDisease progressionOvarian cancerDisease prognosisAverage ageLevels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence
Yu H, Nicar M, Shi R, Berkel H, Nam R, Trachtenberg J, Diamandis E. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology 2001, 57: 471-475. PMID: 11248622, DOI: 10.1016/s0090-4295(00)01003-7.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCase-Control StudiesDisease ProgressionEnzyme-Linked Immunosorbent AssayHumansInsulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm, ResidualProstate-Specific AntigenProstatic NeoplasmsConceptsPostoperative serum samplesInsulin-like growth factor IIGFBP-3IGFBP-2Growth factor IProstate cancerSerum levelsSerum samplesFactor IIGFBP-2 levelsIGFBP-3 levelsIGF-I levelsGroup of patientsLow serum levelsProstate cancer patientsProstate cancer recurrenceProtein 2Recurrent diseaseDisease recurrenceMedian timePrognostic valueCancer patientsRadical prostatectomyCancer recurrenceSerum collection
1999
Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination
Yu H, Levesque M, Clark G, Diamandis E. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. British Journal Of Cancer 1999, 81: 490-495. PMID: 10507775, PMCID: PMC2362935, DOI: 10.1038/sj.bjc.6690720.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsBiomarkers, TumorBreast NeoplasmsCarcinomaChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalDNA ReplicationEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGenes, p53HumansLife TablesLymphatic MetastasisMastectomyMultivariate AnalysisNeoplasm ProteinsNeoplasm Recurrence, LocalNeoplasms, Hormone-DependentPloidiesPrognosisProportional Hazards ModelsProstate-Specific AntigenRadiotherapy, AdjuvantReceptors, EstrogenReceptors, ProgesteroneRiskSensitivity and SpecificitySurvival AnalysisSurvival RateTreatment OutcomeTumor Suppressor Protein p53ConceptsEnzyme-linked immunosorbent assayDisease-free survivalBreast cancer patientsCancer patientsRelative riskCox proportional hazards regression analysisProstate-specific antigen expressionProportional hazards regression analysisReceipt of chemotherapyProgesterone receptor statusSteroid hormone receptor analysisHazards regression analysisRecent clinical evidenceLog-rank testKaplan-Meier plotsOverall survival probabilityHormone receptor analysisPrimary breast carcinomaQuantitative enzyme-linked immunosorbent assayProstate-specific antigenP53 expression statusAssessment of p53Breast cancer prognosisS-phase fractionExpression of p53
1998
The Acid-Labile Subunit of Human Ternary Insulin-Like Growth Factor Binding Protein Complex in Serum: Hepatosplanchnic Release, Diurnal Variation, Circulating Concentrations in Healthy Subjects, and Diagnostic Use in Patients with Growth Hormone Deficiency
Juul A, Møller S, Mosfeldt-Laursen E, Rasmussen M, Scheike T, Pedersen S, Kastrup K, Yu H, Mistry J, Rasmussen S, Müller J, Henriksen J, Skakkebæk N. The Acid-Labile Subunit of Human Ternary Insulin-Like Growth Factor Binding Protein Complex in Serum: Hepatosplanchnic Release, Diurnal Variation, Circulating Concentrations in Healthy Subjects, and Diagnostic Use in Patients with Growth Hormone Deficiency. The Journal Of Clinical Endocrinology & Metabolism 1998, 83: 4408-4415. PMID: 9851786, DOI: 10.1210/jcem.83.12.5311.Peer-Reviewed Original ResearchConceptsAcid-labile subunitIGFBP-3GH deficiencyALS levelsHepatosplanchnic releaseNormal age-related rangesChildhood-onset GH deficiencyInsulin-like growth factorAge-related rangeSignificant arteriovenous gradientNormal GH responseGH secretory statusConcentrations of IGFLiver vein catheterizationGrowth hormone deficiencyCirculating ConcentrationsGH responseGHD patientsVein catheterizationSecretory statusArteriovenous gradientHormone deficiencyHealthy subjectsDiagnostic utilityIGF